Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology

• DOI: 10.1002/ags3.12719
• Publication Date: 2023-07-18T14:25:48Z
• Authors: Takamichi Igarashi; Mina Fukasawa; Toru Watanabe; Nana Kimura; Ayaka Itoh; Haruyoshi Tanaka; Kazuto Shibuya; Isaku Yoshioka; Kenichi Hirabayashi; Tsutomu Fujii
• Keywords: 03 medical and health sciences; 0302 clinical medicine; RD1-811; pancreatic cancer; staging laparoscopy; Surgery; peritoneal washing cytology; RC799-869; Original Articles; Diseases of the digestive system. Gastroenterology

AbstractIntroductionThe prognosis of pancreatic ductal adenocarcinoma (PDAC) in patients with positive peritoneal washing cytology (CY1) is poor. We aimed to evaluate the results of staging laparoscopy (SL) and treatment efficacy in CY1 patients based on a resectability classification.MethodsWe retrospectively reviewed 250 patients with PDAC who underwent SL before the initial treatment between 2017 and 2023 at the University of Toyama.ResultsThe breakdown of cases by resectability classification was resectable (R):borderline resectable (BR):unresectable locally advanced (UR‐LA) = 131:48:71 cases. The frequency of CY1 increased in proportion to the degree of local progression (R:BR:UR‐LA = 20:23:34%), but the frequencies of liver metastasis or peritoneal dissemination were comparable (R:BR:UR‐LA = 6.9:6.3:8.5%). Most CY1 patients received gemcitabine along with nab‐paclitaxel therapy. The CY‐negative conversion rates (R:BR:UR‐LA = 70:64:52%) and conversion surgery rates (R:BR:UR‐LA = 40:27:9%) were inversely proportional to the degree of local progression.Comparing H0P0CY1 factors for each classification, patients with H0P0CY1 had significantly more pancreatic body or tail carcinoma and tumor size ≥32 mm in R patients, whereas in BR patients, duke pancreatic monoclonal antigen type 2 (DUPAN‐2) ≥ 230 U/mL was a significant factor. In contrast, no significant factors were observed in UR‐LA patients.ConclusionThe CY1 rates, CY‐negative conversion rates, and conversion surgery rates varied according to local progression. In the case of R and BR, SL could be considered in patients with pancreatic body or tail carcinoma, large tumor size, or high DUPAN‐2 level. In UR‐LA, SL might be considered for all patients.